Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Tuesday 13 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

pharmaphorum podcast Episode 280, Robbie Tyrie, Torridon Cyber

AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie

Robbie Tyrie, founder and managing director of Torridon Cyber, talks cybersecurity when it comes to AI, pharma companies, and health systems.

Digital

Digital representation of AI governance and security

Pharma’s next security problem isn’t the code. It’s what the...

As AI becomes embedded throughout development, innovation must be matched by equally sophisticated approaches to software security.

Digital

Digital pharma suppliers

Changing Faces: Digital and supplier hires, September 2026

September brought leadership changes across businesses providing technology, research, manufacturing, and professional services to the life sciences.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Market Access

Magnifying glass over pills scattered over dollar and euro notes

One year after MFN: How US policy is reshaping the global ph...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

Articles

First test case of NICE approach to Highly Specialised Technologies – Soliris® (eculizumab)

First test case of NICE approach to Highly Specialised Techn...

In the first test for the new Highly Specialised Technologies (HST) process for the UK's medicines cost effectiveness watchdog NICE, Leela Barham analyses the situation with Alexion's Solaris,

Articles

The race for pharma to embrace real-world evidence

The race for pharma to embrace real-world evidence

After attending Adelphi's Renaissance event in Paris, focussed on how real-world evidence is impacting the pharma industry, Paul Tunnah sees comparative challenges between perfection and realit

Articles

Rare disease patients are talking – are you listening?

Rare disease patients are talking – are you listening?

Brian Loew and Sharon Terry explore the benefits of listening to the online conversations of rare disease patients and how researchers can help rare disease patients to connect for the benefit

Load more results

Sales & Marketing

Sales & Marketing

Klick Health and Oxford PharmaGenesis

Why Klick Health, Oxford PharmaGenesis chose to join forces

Leadership from Klick Health and Oxford PharmaGenesis discuss their

Sales & Marketing

Day One Strategy white paper

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Digital

Digital

pharmaphorum podcast Episode 280, Robbie Tyrie, Torridon Cyber

AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie

Robbie Tyrie, founder and managing director of Torridon Cyber, talks cybersecurity when it comes to AI, pharma companies, and health systems.

Digital

Digital representation of AI governance and security

Pharma’s next security problem isn’t the code. It’s what the...

As AI becomes embedded throughout development, innovation must be matched by equally sophisticated approaches to software security.

Market Access

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Market Access

Magnifying glass over pills scattered over dollar and euro notes

One year after MFN: How US policy is reshaping the global ph...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

Editor's Picks

MSD ordered to pull injectable Keytruda from sale in Europe

PhRMA sues Trump administration over GLOBE rebate scheme

UK watchdog takes first action on oral weight drug adverts

Click claims FDA okay for first-in-class schizophrenia DTx

New York declares measles outbreak a "disaster emergency"

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Dr Michael Bauer and Jonah Comstock

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

Cancer cell and T-cells

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

T-cells in action

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Patients

Patients

Hispanic heritage

Breaking Bipolar I disorder stigma in the Hispanic community

For many Hispanic patients and families, that is where the gap between need and treatment can begin.

Patients

World Sight Day

Durability and earlier access could reshape diabetic retinop...

This year’s World Sight Day turns global attention to the scale of preventable vision loss

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

R&D

R&D

Man in hiring process

Changing Faces: Pharma and biotech hires, September 2026

There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Digital representation of sepsis bacteria attacking heart

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

Editor's Picks

MSD ordered to pull injectable Keytruda from sale in Europe

PhRMA sues Trump administration over GLOBE rebate scheme

UK watchdog takes first action on oral weight drug adverts

Click claims FDA okay for first-in-class schizophrenia DTx

New York declares measles outbreak a "disaster emergency"

News

BioNTech HQ

BioNTech sticks with cancer vaccine despite trial miss

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company